This study will determine the maximum tolerated dose and pharmacokinetic profile of R1507 in patients with metastatic or locally advanced malignant solid tumors, non-Hodgkin's lymphoma or Hodgkin's lymphoma. Groups of patients will be sequentially enrolled to receive ascending doses of R1507 either weekly or three-weekly by intravenous infusion. The starting dose of 1mg/kg iv for each dosing regimen will be escalated in subsequent groups of patients after a satisfactory assessment of safety, tolerability and pharmacokinetics of the previous dose. The anticipated time on study treatment is until disease progression or dose-limiting toxicity, and the target sample size is <100 individuals.

Inclusion Criteria:

• adult patients, >=18 years of age;
• solid neoplasm, non-Hodgkin's lymphoma or Hodgkin's lymphoma;
• metastatic or locally advanced disease, not curable by any currently available treatment.

Exclusion Criteria:

• severe, uncontrolled systemic disease;
• patients who require treatment with glucocorticoids or immunosuppressive treatment within last 6 months;
• patients with diabetes mellitus.